Advertisement

Topics

Global Approvals Analysis: Diabetes, Drug-Eluting Stents Lead List Of Non-US Approvals in October

12:04 EST 8 Nov 2017 | SCRIP

The CE Marks recorded in October include Abbott's new version of Xience and Medinol's BioNIR drug-eluting coronary stents, plus 18...

      

Related Stories

 

Original Article: Global Approvals Analysis: Diabetes, Drug-Eluting Stents Lead List Of Non-US Approvals in October

NEXT ARTICLE

More From BioPortfolio on "Global Approvals Analysis: Diabetes, Drug-Eluting Stents Lead List Of Non-US Approvals in October"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Abbott
The 11th largest pharmaceutical company in the world, <!--LGfEGNT2Lhm-->Abbott Laboratories generated sales of $16 billion in 2009 and has 90,000 employees. Within the <!--LGfEGNT2Lhm-->medical device arm of the company, products of note ar...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...